No profile data available.
Pharming Group N.v. (PHAR) is a healthcare company in the immunodeficiency treatment drugs industry, based in Leiden, Netherlands, with about 407 full-time employees.
It reported revenue of $297.20 million for fiscal year 2024, up 21.1% from fiscal year 2023, and net income of -$11.84 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $97.29 million, up 30.0% from a year before. Its largest business segment, Ruconest®, brought in 85% of segment revenue in fiscal year 2025; United States was the largest region with 96%. Its market capitalization was $692.92 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
, a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.
Pharming Group reported $297.20 million in revenue for fiscal year 2024, up 21.1% from $245.32 million in fiscal year 2023. In Q3 2025 revenue was $97.29 million.
Ruconest®, with 317.92 million EUR or 85% of segment revenue in fiscal year 2025. Next: Joenja® (15%).
United States: 96% of revenue by region in fiscal year 2025, followed by Europe and The Rest of The World (4%).
$692.92 million as of October 9, 2026.
Listed companies of a similar size in the same industry (immunodeficiency treatment drugs) include BioCryst Pharmaceuticals, Inc. (BCRX), Pharvaris N.v. (PHVS), X4 Pharmaceuticals, Inc. (XFOR), AIM ImmunoTech Inc. (AIM).